S
Sylvia Musto
Researcher at Pfizer
Publications - 28
Citations - 1245
Sylvia Musto is an academic researcher from Pfizer. The author has contributed to research in topics: Paclitaxel & Antibody-drug conjugate. The author has an hindex of 17, co-authored 28 publications receiving 1096 citations.
Papers
More filters
Journal ArticleDOI
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules
Malathi Hari,Frank Loganzo,Tami Annable,Xingzhi Tan,Sylvia Musto,Daniel B. Morilla,James H. Nettles,James P. Snyder,Lee M. Greenberger +8 more
TL;DR: It is suggested that a mutation in tubulin might affect microtubule stability as well as drug binding and contribute to the observed resistance profile.
Journal ArticleDOI
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments
Frank Loganzo,Xingzhi Tan,Matthew Sung,Guixian Jin,Jeremy S. Myers,Eugene Melamud,Fang Wang,Veronica Diesl,Maximillian T. Follettie,Sylvia Musto,My-Hanh Lam,William T. Hu,Manoj Charati,Kiran Khandke,Kenny Sung Kyoo Kim,Mike Cinque,Judy Lucas,Edmund I. Graziani,Andreas Maderna,Christopher J. O’Donnell,Kim Arndt,Hans-Peter Gerber +21 more
TL;DR: In this article, a trastuzumab-maytansinoid ADC (TM-ADC) was applied to breast cancer cell lines, and the authors found that the ADC-resistant cells, 361-TM and JIMT1-TM, were characterized by cytotoxicity, proteomic, transcriptional and other profiling.
Journal Article
HTI-286, a Synthetic Analogue of the Tripeptide Hemiasterlin, Is a Potent Antimicrotubule Agent that Circumvents P-Glycoprotein-mediated Resistance in Vitro and in Vivo
Frank Loganzo,Carolyn M Discafani,Tami Annable,Carl Beyer,Sylvia Musto,Malathi Hari,Xingzhi Tan,Carolyn Hardy,Richard Hernandez,Michelle Baxter,Thiruvikraman Singanallore,Gulnaz Khafizova,Marianne S. Poruchynsky,Tito Fojo,James A. Nieman,Semiramis Ayral-Kaloustian,Arie Zask,Raymond J. Andersen,Lee M. Greenberger +18 more
TL;DR: The data suggest that HTI-286 has excellent preclinical properties that may translate into superior clinical activity, as well as provide a useful synthetic reagent to probe the drug contact sites of peptide-like molecules that interact with tubulin.
Journal ArticleDOI
Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications
Andreas Maderna,Matthew David Doroski,Chakrapani Subramanyam,Alexander M. Porte,Carolyn A. Leverett,Beth C. Vetelino,Zecheng Chen,Hud Lawrence Risley,Kevin D. Parris,Jayvardhan Pandit,Alison H. Varghese,Suman Shanker,Cynthia Song,Sai Chetan K. Sukuru,Kathleen A. Farley,Melissa Wagenaar,Michael J. Shapiro,Sylvia Musto,My-Hanh Lam,Frank Loganzo,Christopher J. O’Donnell +20 more
TL;DR: The design and synthesis of several new auristatins with N-terminal modifications that include amino acids with α,α-disubstituted carbon atoms are described, including the discovery of the lead auristatin, PF-06380101.
Journal ArticleDOI
Synthesis, molecular editing, and biological assessment of the potent cytotoxin leiodermatolide.
Damien Mailhol,Jens Willwacher,Nina Kausch-Busies,Elizabeith E. Rubitski,Zhanna Sobol,Maik Schuler,My-Hanh Lam,Sylvia Musto,Frank Loganzo,Andreas Maderna,Alois Fürstner +10 more
TL;DR: The acquired biodata show that 1 is a potent cytotoxin in human tumor cell proliferation assays, distinguished by GI50 values in the ≤3 nM range even for cell lines expressing the Pgp efflux transporter.